<span id="o9s2o"></span>

      <button id="o9s2o"></button>
      <dd id="o9s2o"><track id="o9s2o"></track></dd>

    1. <rp id="o9s2o"><acronym id="o9s2o"><u id="o9s2o"></u></acronym></rp>

    2. <th id="o9s2o"></th>
      1. <li id="o9s2o"></li>
      2. <th id="o9s2o"><pre id="o9s2o"><sup id="o9s2o"></sup></pre></th>
      3. <span id="o9s2o"></span>

              <dd id="o9s2o"></dd>
            1. <th id="o9s2o"></th>

              <th id="o9s2o"></th>
              +86 400-821-9890

              Biomarker
              Discovery

              By utilizing our big panel comprehensive genomic
              profiling test, we collaborate with our partners in
              biomarker discovery and biomarker-driven drug
              development-from target discovery to
              commercial launch.

              Fusion-Based Biomarkers
              for Targeted Therapy

              We have integrated DNA and RNA sequencing results
              for detection of fusion genes with higher sensitivity.

              DNA+RNA-based analysis
              of Fusion

              RNA sequencing is a supplement to fusion detection

              In Chinese solid tumor cohort, 60.2% of fusion could be identified both in DNA&RNA, 21.4% of fusion was DNA only and 18.4% was RNA only.

              Gene fusions

              Overview of gene rearrangement in Chinese cohort including kinase gene fusions and LOF rearrangement of tumor suppressor genes. Different driver genes and their partners were identified in the cohort. The thickness of the line indicated the number of cases with relative gene rearrangement.

              NTRK family gene fusions

              Among 5,388 clinical cases, 22 ( 0.4% ) patients were found harboring NTRK1/3 fusions by next-generation sequencing testing, which was further confirmed by pan-Trk IHC or PCR.
              NTRK fusions were detected more in fibrosarcoma and colorectal cancer at a ratio of 11.1% and 1.1%, respectively.

              FGFR family gene fusions

              From over 4,000 solid tumor patients, 6.6% had FGFR 1-4 variations. The incidences of genomic alterations on FGFR1, 2, 3, and 4 were 2.8%, 1.6%, 1.2% and 1%, respectively. Amplification was the most common variation type of FGFR, which accounted for 47% of all the genomic alterations, followed by mutations (41.5%) and fusions (11.4%).


              Targeted Therapy

              BRCA1/2

              The 5000+ Chinese solid tumor patients included 58.3% males and 41.7% females. Among patients with BRCA1/2 mutations,74.7% patients harbored somatic mutations. 24.3% patients harbored germline mutations and 1.0% patients harbored both somatic and germline mutations.

              ERBB2

              Distriution and frequency of ERBB2 variants in 5000+ Chinese solid tumor patients.


              Immuno-Oncology

              We have leveraged multiple techniques (DNA, RNA, IHC, etc.) to help identify
              immunotherapy-related biomarkers for our patients.

              TMB

              The landscape of tumor mutational burden (TMB)in 10,000+ Chinese solid tumor patients.

              PD-L1

              The landscape of PD-L1 expression on varoius types of tumor cells in 3,000+ Chinese solid tumor patients.

              韩国三级在线观看久 很黄很刺激的18禁网站| 无限资源在线观看中文| 好男人视频手机在线观看| 亚洲日本人成网站在线播放| 免费无码午夜福利电影网| 成年女人看片免费视频播放人| 中文无码福利视频岛国片| 日本亚洲欧美日韩国产ay| 国产精品自产拍在线观看| 护士巨好爽好大乳| 久久w5ww成w人免费|